Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2010-11 trivalent inactivated influenza vaccine (British Columbia Centre for Disease Control)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 2010-11 trivalent inactivated influenza vaccine (TIV) is a seasonal vaccine designed to protect against three strains of the influenza virus: two influenza A strains (H1N1 and H3N2) and one influenza B strain. For the 2010-2011 Northern Hemisphere season, the WHO-recommended formulation included antigens from A/California/7/2009 (H1N1)pdm09-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like (Victoria lineage) viruses. This specific formulation was notable for being the first seasonal vaccine to incorporate the 2009 H1N1 pandemic strain as the standard seasonal H1N1 component. The vaccine works by inducing the production of neutralizing antibodies against the viral hemagglutinin (HA) protein, which prevents the virus from attaching to and entering host cells. It is typically administered via intramuscular injection and is produced by multiple global manufacturers following annual WHO strain recommendations.
- Brand names
- FluviralVaxigripAgrifluInfluvacIntanza
- Other names
- 2010-2011 TIV2010-2011 seasonal influenza vaccine2010-11 trivalent inactivated influenza vaccine
02
Targets
HA (Hemagglutinin)TLR7/8 (Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8))HA (Hemagglutinin [Influenza A virus (A/Perth/16/2009(H3N2))])H1 HA (Influenza A hemagglutinin H1)Neuraminidase
Beyond the preview
Go deeper on 2010-11 trivalent inactivated influenza vaccine (British Columbia Centre for Disease Control).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2010-11 trivalent inactivated influenza vaccine (British Columbia Centre for Disease Control).